|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-10-22
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase inhibitor administered once-daily in patients with advanced multiple myeloma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4233-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19846979-Administration, Oral,
pubmed-meshheading:19846979-Antineoplastic Agents,
pubmed-meshheading:19846979-Dose-Response Relationship, Drug,
pubmed-meshheading:19846979-Drug Administration Schedule,
pubmed-meshheading:19846979-Female,
pubmed-meshheading:19846979-Humans,
pubmed-meshheading:19846979-Indoles,
pubmed-meshheading:19846979-Male,
pubmed-meshheading:19846979-Multiple Myeloma
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
|
|
pubmed:affiliation |
Department of Medicine/Haematology and Oncology, University of Muenster Albert-Schweitzer-Str. 33, D-48129 Muenster, Germany. martin.kropff@ukmuenster.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
